Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area tgf tgf bcr abl'

Search results for: 'research area tgf tgf bcr abl'

Items 11-18 of 18

Page
per page
  1. PD 180970
    A8606 PD 180970
    Summary: P210bcr/abl tyrosine kinase inhibitor
      <21.46 mg/mL
  2. Bafetinib (INNO-406)
    B1011 Bafetinib (INNO-406)
     2 Citation
    Summary: Bcr-Abl/Lyn tyrosine kinase inhibitor
      ≥57.7 mg/mL
  3. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL
  4. PD173955
    A8812 PD173955
    Target: Bcr-Abl|Src
    Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,
      ≥22.15 mg/mL
  5. DCC-2036 (Rebastinib)
    B1404 DCC-2036 (Rebastinib)
    Target: FLT3|Bcr-Abl|Tie-2|KDR
    Summary: Bcr-Abl inhibitor
      ≥27.7 mg/mL
  6. Nilotinib monohydrochloride monohydrate
    A3660 Nilotinib monohydrochloride monohydrate
    Summary: Bcr-Abl inhibitor
      ≥50 mg/mL
  7. GNF-7
    B6033 GNF-7
    Summary: Type II Bcr-Abl inhibitor
      insoluble in EtOH; insoluble in H2O; ≥5.48 mg/mL
  8. AG957
    C5826 AG957
    Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins

Items 11-18 of 18

Page
per page